Login / Signup

Risk of cardiovascular disease in patients with multiple sclerosis treated with fingolimod compared to natalizumab: A nationwide cohort study of 2095 patients in Denmark.

Elisabeth FramkeLau Caspar ThygesenMorten MalmborgMorten SchouFinn SellebjergMelinda Magyari
Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2024)
We found an increased risk of CVD in patients with MS treated with fingolimod. This increased risk was mainly due to hypertension.
Keyphrases
  • multiple sclerosis
  • cardiovascular disease
  • blood pressure
  • type diabetes
  • mass spectrometry
  • ms ms
  • cross sectional
  • newly diagnosed
  • metabolic syndrome